PDE5A and benign prostatic hyperplasia: Tadalafil (Cialis; Eli Lilly Indianapolis, Indiana), sildenafil (Viagra; Pfizer New York, New York), and vardenafil (Levitra; Bayer Leverkusen, Germany) are oral phosphodiesterase type 5 (PDE5) inhibitors and have been extensively evaluated for their efficacy in managing BPH-associated ED and LUTS [26–28].